BRPI0514537A - compostos de aminoeteroarila substituìdo com pirazol como inibidores de proteìna quinase - Google Patents

compostos de aminoeteroarila substituìdo com pirazol como inibidores de proteìna quinase

Info

Publication number
BRPI0514537A
BRPI0514537A BRPI0514537-6A BRPI0514537A BRPI0514537A BR PI0514537 A BRPI0514537 A BR PI0514537A BR PI0514537 A BRPI0514537 A BR PI0514537A BR PI0514537 A BRPI0514537 A BR PI0514537A
Authority
BR
Brazil
Prior art keywords
compounds
protein kinase
kinase inhibitors
aminoetheroyl
pyrazol
Prior art date
Application number
BRPI0514537-6A
Other languages
English (en)
Inventor
Jingrong Jean Cui
Lee Andrew Funk
Lei Jia
Pei-Pei Kung
Jerry Jialun Meng
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35677463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514537(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0514537A publication Critical patent/BRPI0514537A/pt
Publication of BRPI0514537B1 publication Critical patent/BRPI0514537B1/pt
Publication of BRPI0514537B8 publication Critical patent/BRPI0514537B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPOSTOS DE ANINOETEROARILA SUBSTITUìDOS COM PIRAZOL COMO INIBIDORES DE PROTEìNA QUINASE São fornecidos compostos de Fórmula I, assim como métodos para sua síntese e uso. Os compostos preferidos são potentes inibidores de c-Met proteína quinase, e são úteis no tratamento de distúrbios de crescimento anormal da célula, tais como cânceres.
BRPI0514537A 2004-08-26 2005-08-15 compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende BRPI0514537B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60524404P 2004-08-26 2004-08-26
US60/605,244 2004-08-26
US69080305P 2005-06-14 2005-06-14
US60/690,803 2005-06-14
PCT/IB2005/002695 WO2006021881A2 (en) 2004-08-26 2005-08-15 Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors

Publications (3)

Publication Number Publication Date
BRPI0514537A true BRPI0514537A (pt) 2008-06-17
BRPI0514537B1 BRPI0514537B1 (pt) 2020-05-12
BRPI0514537B8 BRPI0514537B8 (pt) 2021-05-25

Family

ID=35677463

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514537A BRPI0514537B8 (pt) 2004-08-26 2005-08-15 compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende

Country Status (44)

Country Link
US (1) US20060128724A1 (pt)
EP (1) EP1784396B8 (pt)
JP (1) JP4167295B2 (pt)
KR (1) KR100869393B1 (pt)
CN (1) CN101018780B (pt)
AP (1) AP2332A (pt)
AR (1) AR050529A1 (pt)
AT (1) ATE492544T1 (pt)
AU (1) AU2005276132B2 (pt)
BR (1) BRPI0514537B8 (pt)
CA (1) CA2577937C (pt)
CR (2) CR8938A (pt)
CY (1) CY1111138T1 (pt)
DE (1) DE602005025499D1 (pt)
DK (1) DK1784396T3 (pt)
EA (1) EA011725B1 (pt)
EC (1) ECSP077278A (pt)
ES (1) ES2355923T3 (pt)
GE (1) GEP20094845B (pt)
GT (1) GT200500226A (pt)
HK (1) HK1105415A1 (pt)
HN (1) HN2005000477A (pt)
HR (1) HRP20110116T1 (pt)
IL (1) IL181045A0 (pt)
MA (1) MA28827B1 (pt)
ME (1) ME01309B (pt)
MX (1) MX2007002310A (pt)
MY (1) MY139942A (pt)
NI (1) NI200700058A (pt)
NL (1) NL1029809C2 (pt)
NO (1) NO338656B1 (pt)
NZ (1) NZ552946A (pt)
PA (1) PA8643201A1 (pt)
PE (1) PE20060651A1 (pt)
PL (1) PL1784396T3 (pt)
PT (1) PT1784396E (pt)
RS (1) RS51601B (pt)
SI (1) SI1784396T1 (pt)
SV (1) SV2006002208A (pt)
TN (1) TNSN07071A1 (pt)
TW (1) TWI300411B (pt)
UY (1) UY29080A1 (pt)
WO (1) WO2006021881A2 (pt)
ZA (1) ZA200701281B (pt)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA13151A (en) * 2003-02-26 2006-12-13 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors.
WO2006021884A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US20070072908A1 (en) * 2005-06-08 2007-03-29 Japan Tobacco Inc. Heterocyclic compounds
US7825137B2 (en) * 2005-12-05 2010-11-02 Pfizer Inc. Method of treating abnormal cell growth
ES2402419T3 (es) * 2005-12-05 2013-05-03 Pfizer Products Inc. Polimorfos de un inhibidor de C-MET/HGFR
WO2008051808A2 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
GB0621607D0 (en) * 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
WO2008071451A1 (en) 2006-12-14 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Dihydropyridine derivatives useful as protein kinase inhibitors
EP2120578B1 (en) * 2007-01-19 2014-11-19 Xcovery, INC. Kinase inhibitor compounds
WO2008127710A2 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute Methods for treating cancer resistant to erbb therapeutics
US8263585B2 (en) 2007-05-04 2012-09-11 Novartis Ag Organic compounds
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
WO2009036404A2 (en) 2007-09-13 2009-03-19 Codexis, Inc. Ketoreductase polypeptides for the reduction of acetophenones
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
EP2265270A1 (en) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
JPWO2009131173A1 (ja) 2008-04-23 2011-08-18 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
KR101034351B1 (ko) * 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물
NZ590542A (en) 2008-06-19 2012-12-21 Xcovery Holding Co Llc Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
EP2356116A1 (en) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
DE102009003975A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
AU2010254053A1 (en) * 2009-05-28 2011-12-01 Vertex Pharmaceuticals Incorporated Substituted pyrazole inhibitors of c-Met protein kinase
TW201105662A (en) 2009-07-07 2011-02-16 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
CA2780922A1 (en) * 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
MX2012009720A (es) * 2010-02-22 2012-10-09 Glaxosmithkline Llc Triazolonas como inhibidores de acido graso sintasa.
US20120329826A1 (en) 2010-03-03 2012-12-27 OSI Pharmaceuticals,. LLC Substituted-5-aminopyrrolo/pyrazolopyridines
EP2566858A2 (en) * 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
US8513238B2 (en) * 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
KR101871436B1 (ko) 2010-05-17 2018-06-27 인코젠 쎄라퓨틱스 프라이빗 리미티드 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
CN101857594B (zh) * 2010-06-18 2013-04-03 南方医科大学 一种四氢吡啶并吲哚类化合物及其制备方法和应用
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
JP5810157B2 (ja) * 2010-07-09 2015-11-11 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ プロテインキナーゼ阻害剤および処置の方法
CN101967140A (zh) * 2010-09-14 2011-02-09 郑州泰基鸿诺药物科技有限公司 氘代克里唑蒂尼及其衍生物、制备方法和应用
WO2012048259A2 (en) 2010-10-08 2012-04-12 Xcovery Holding Company, Llc Substituted pyridazine carboxamide compounds
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
CN102850328B (zh) * 2011-07-01 2014-12-24 苏州东南药业股份有限公司 吡啶类化合物、其制备方法、包含该化合物的药物组合物及其用途
WO2013013308A1 (en) * 2011-07-27 2013-01-31 Beta Pharma Canada Inc. Spirocyclic molecules as protein kinase inhibitors
US20160206608A1 (en) * 2011-08-02 2016-07-21 Pfizer Inc. Crizotinib for use in the treatment of cancer
US20140350050A1 (en) * 2011-09-21 2014-11-27 Teligene Ltd. Pyridine compounds as inhibitors of kinase
CN103087050A (zh) * 2011-10-28 2013-05-08 山东轩竹医药科技有限公司 芳基激酶抑制剂
AP2014007881A0 (en) 2012-03-06 2014-08-31 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
CN103304552B (zh) * 2012-03-09 2016-12-28 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
WO2013138210A1 (en) * 2012-03-14 2013-09-19 Ning Xi Substituted cyclic compounds and methods of use
EP2852586A1 (en) 2012-03-16 2015-04-01 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
CN103319468B (zh) * 2012-03-21 2016-07-13 广东东阳光药业有限公司 取代的螺双环化合物及其使用方法和用途
WO2013144191A1 (de) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
SG11201406185WA (en) 2012-03-30 2014-11-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103373986B (zh) * 2012-04-22 2016-10-05 东南大学 克里唑替尼前药及其制备方法与用途
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
WO2013181251A1 (en) 2012-05-29 2013-12-05 Ratiopharm Gmbh Crizotinib hydrochloride salt in crystalline
GB201211310D0 (en) * 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
WO2014020467A2 (en) 2012-07-30 2014-02-06 Fresenius Kabi Oncology Ltd Process for the preparation of pyrazole substituted aminoheteroaryl compounds
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
JP2015529665A (ja) * 2012-08-27 2015-10-08 ツェーエムエム−フォルシュングスツェントルム フュア モレクラレ メディツィン ゲーエムベーハー Ｍｔｈ１阻害剤としてのアミノヘテロアリール化合物
CN103720691A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2014081816A1 (en) * 2012-11-21 2014-05-30 Concert Pharmaceuticals, Inc. Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2014111496A1 (en) * 2013-01-18 2014-07-24 F. Hoffmann-La Roche Ag 3-substituted pyrazoles and use as dlk inhibitors
WO2014117718A1 (zh) * 2013-02-02 2014-08-07 正大天晴药业集团股份有限公司 取代的2-氨基吡啶类蛋白激酶抑制剂
CN103992307B (zh) * 2013-02-16 2017-07-14 浙江九洲药物科技有限公司 一种克里唑替尼的制备方法
WO2014139391A1 (en) * 2013-03-11 2014-09-18 Teligene Ltd Substituted pyridine compounds as kinases inhibitors
EA030481B1 (ru) 2013-03-14 2018-08-31 Эпизим, Инк. Ингибиторы аргининметилтрансферазы и их применения
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
CA2903264A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9045455B2 (en) 2013-03-14 2015-06-02 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
CN104059054B (zh) * 2013-03-19 2018-11-20 浙江导明医药科技有限公司 用于治疗癌症的三级环状胺alk激酶抑制剂
WO2014203177A1 (en) * 2013-06-18 2014-12-24 Shilpa Medicare Limited Amorphous (r) -3- [1- (2, 6-dichloro-3-fluorophenyl) methoxy] -5- [1- (piperidin-4- yl) -1h-pyrazol-4-yl] pyridin-2-amine
CN104230890A (zh) * 2013-06-19 2014-12-24 信诺凯（北京）化工有限公司 吡啶-2-胺衍生物及其制法和药物组合物与用途
CN104650049B (zh) * 2013-08-28 2018-06-08 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
KR101598664B1 (ko) 2013-09-04 2016-03-02 씨제이헬스케어 주식회사 피롤로피리다진 유도체를 포함하는 단백질 키나제 억제제
WO2015034729A1 (en) * 2013-09-05 2015-03-12 Calitor Sciences, Llc Substituted pyridine compounds and methods of use
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3053923B1 (en) 2013-09-30 2018-04-11 Korea Research Institute of Chemical Technology Triazolopyrazine derivatives as tyrosin kinase inhibitors
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
WO2015172747A1 (en) * 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
WO2016044576A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
CN104402868B (zh) * 2014-11-04 2016-08-24 郑州泰基鸿诺医药股份有限公司 氘代克里唑蒂尼晶型及其制备方法
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016145383A1 (en) * 2015-03-11 2016-09-15 Board Of Regents, University Of Texas System Mth1 inhibitors for treating disease
WO2016169504A1 (zh) 2015-04-24 2016-10-27 广州再极医药科技有限公司 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
CN106279112A (zh) * 2015-06-12 2017-01-04 浙江九洲药业股份有限公司 一种克里唑替尼中间体及其制备方法和应用
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
IL292302B2 (en) 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
TWI646094B (zh) 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN106632260B (zh) * 2016-09-29 2019-04-26 上海天慈生物谷生物工程有限公司 一种小分子激酶抑制剂的制备方法
AU2018271862B2 (en) 2017-05-23 2022-12-15 Mei Pharma, Inc. Combination therapy
US11351176B2 (en) 2017-08-14 2022-06-07 Mei Pharma, Inc. Combination therapy
CN110372664A (zh) * 2018-04-13 2019-10-25 华东理工大学 选择性jak2抑制剂及其应用
KR102207608B1 (ko) 2019-04-24 2021-01-26 윤종오 카르복실산으로 유기화된 규소 이온 복합체 및 복합체의 제조방법과 이를 이용한 제품

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en) * 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0821671B1 (en) * 1995-04-20 2000-12-27 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO1997049700A1 (en) * 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
JPH11236333A (ja) * 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
BR9913315A (pt) * 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
NZ509372A (en) * 1998-08-27 2003-08-29 Pfizer Prod Inc Substituted quinolin-2-one derivatives, pharmaceuticals thereof and their use for treating abnormal cell growth (e.g. cancer)
EP1006113A1 (en) * 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
TR200201297T2 (tr) * 1999-02-11 2002-06-21 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.
US6586447B1 (en) * 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
EP1081137A1 (en) * 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
ES2212971T3 (es) * 1999-11-30 2004-08-16 Pfizer Products Inc. Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
JP2005526026A (ja) * 2002-02-06 2005-09-02 イシウム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ イエルサレム カテコール生物学的等価体
WO2004004720A1 (en) * 2002-07-03 2004-01-15 Astex Technology Limited 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
WO2004013091A2 (en) * 2002-08-01 2004-02-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DE10307845A1 (de) * 2003-02-25 2004-09-02 Bayer Cropscience Gmbh Heterocyclische Amide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
OA13151A (en) * 2003-02-26 2006-12-13 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors.
WO2006021884A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors

Also Published As

Publication number Publication date
AP2332A (en) 2011-12-05
CY1111138T1 (el) 2015-06-11
EP1784396B8 (en) 2011-04-20
AR050529A1 (es) 2006-11-01
AU2005276132B2 (en) 2011-09-29
GT200500226A (es) 2006-04-10
WO2006021881A2 (en) 2006-03-02
PT1784396E (pt) 2011-01-27
EA011725B1 (ru) 2009-04-28
CR20120421A (es) 2012-09-14
NO20071320L (no) 2007-05-29
SI1784396T1 (sl) 2011-03-31
SV2006002208A (es) 2006-10-04
WO2006021881A3 (en) 2006-05-18
ATE492544T1 (de) 2011-01-15
US20060128724A1 (en) 2006-06-15
BRPI0514537B8 (pt) 2021-05-25
DE602005025499D1 (de) 2011-02-03
MX2007002310A (es) 2007-05-08
JP4167295B2 (ja) 2008-10-15
RS51601B (en) 2011-08-31
MY139942A (en) 2009-11-30
PL1784396T3 (pl) 2011-05-31
ECSP077278A (es) 2007-03-29
IL181045A0 (en) 2007-07-04
CR8938A (es) 2007-08-14
AP2007003906A0 (en) 2007-02-28
CN101018780A (zh) 2007-08-15
HK1105415A1 (en) 2008-04-03
ZA200701281B (en) 2008-12-31
NZ552946A (en) 2010-09-30
PE20060651A1 (es) 2006-07-19
CN101018780B (zh) 2012-01-11
DK1784396T3 (da) 2011-02-14
AU2005276132A1 (en) 2006-03-02
TW200621751A (en) 2006-07-01
UY29080A1 (es) 2006-03-31
KR100869393B1 (ko) 2008-11-21
TWI300411B (en) 2008-09-01
NO338656B1 (no) 2016-09-26
GEP20094845B (en) 2009-11-25
ME01309B (me) 2013-12-20
NI200700058A (es) 2008-03-07
TNSN07071A1 (fr) 2008-06-02
NL1029809C2 (nl) 2006-10-17
NL1029809A1 (nl) 2006-02-28
HN2005000477A (es) 2010-06-09
EP1784396A2 (en) 2007-05-16
CA2577937A1 (en) 2006-03-02
PA8643201A1 (es) 2006-06-02
EA200700321A1 (ru) 2007-08-31
JP2008510788A (ja) 2008-04-10
KR20070038569A (ko) 2007-04-10
EP1784396B1 (en) 2010-12-22
ES2355923T3 (es) 2011-04-01
CA2577937C (en) 2010-12-21
HRP20110116T1 (hr) 2011-03-31
BRPI0514537B1 (pt) 2020-05-12
MA28827B1 (fr) 2007-08-01

Similar Documents

Publication Publication Date Title
BRPI0514537A (pt) compostos de aminoeteroarila substituìdo com pirazol como inibidores de proteìna quinase
BRPI0513915A (pt) compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
BRPI0514687A (pt) compostos amino heteroarila como inibidores de proteìna tirosina cinase
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
BRPI0506802A (pt) derivados de indol e uso destes como inibidores de quinase em inibidores de ikk2 particulares
UY29591A1 (es) Aminopirimidinas como moduladores de quinasas
ECSP088121A (es) Derivados de pirrolo [2,3-b] piridina comoinhibidores de proteina cinasa
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
ME01269B (me) Jedinjenja pirolo (2,3-d) pirimidina
MX2008001538A (es) Aril piridinas y metodos para su uso.
SV2003001148A (es) Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv
CR7961A (es) Compuestos de aminoheteroarilo como inhibidores de las proteinquinasas
NO20076345L (no) Bisykliske derivater som P38-kinaseinhibitorer
EA200801430A1 (ru) Производные триазола
ECSP045219A (es) Derivados de quinazolinona y su uso como agonistas cb
NO20082105L (no) Pyrazoloisokinolinderivater
BRPI0416994A (pt) inibidores de proteìna cinase com base em indolinona avançada
ATE532514T1 (de) Piperidin- und piperazinderivate
UA86083C2 (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
UA92047C2 (uk) Карбоніламінопіролпіразоли - потужні інгібітори кінази
CU20070047A7 (es) Compuestos de aminoheteroarilo enantioméricamente puros como inhibidores de proteína quinasa
DOP2005000155A (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa.
DOP2005000154A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: PFIZER INC. (US)